Biological Products, (No Diagnostic Substances) · DE · CIK 1819790
Develops and commercializes eye care therapeutics, starting with Demodex blepharitis treatment
Comparable business profile · signals at a glance
In the 90 days to Mar 20, 2026: 8 sold $9.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 20, 2026 | Neervannan SeshadriChief Operating Officer | Sell | 2,989 | $66.75 | $200K |
| Mar 19, 2026 | Azamian Bobak R.President/CEO and Board Chair | Sell | 11,964 | $67.00 | $802K |
| Mar 19, 2026 | Neervannan SeshadriChief Operating Officer | Sell | 4,589 | $67.00 | $307K |
| Mar 19, 2026 | Mottiwala AzizChief Commercial Officer | Sell | 4,440 | $67.00 | $297K |
| Mar 19, 2026 | Wahl BryanGeneral Counsel | Sell | 4,231 | $67.00 | $283K |
| Mar 19, 2026 | Whitfield Dianne C.Chief Human Resources Officer | Sell | 4,174 | $67.00 | $280K |
| Mar 19, 2026 | Farrow Jeffrey SSee Remarks | Sell | 2,186 | $67.00 | $146K |
| Mar 19, 2026 | Lin Elizabeth YeuChief Medical Officer | Sell | 390 | $67.00 | $26K |
| Mar 18, 2026 | Azamian Bobak R.President/CEO and Board Chair | Sell | 11,667 | $68.71 | $802K |
| Mar 18, 2026 | Mottiwala AzizChief Commercial Officer | Sell | 4,330 | $68.71 | $298K |
| Mar 18, 2026 | Wahl BryanGeneral Counsel | Sell | 4,125 | $68.71 | $283K |
| Mar 18, 2026 | Whitfield Dianne C.Chief Human Resources Officer | Sell | 4,071 | $68.71 | $280K |
| Mar 18, 2026 | Neervannan SeshadriChief Operating Officer | Sell | 3,610 | $68.71 | $248K |
| Mar 18, 2026 | Farrow Jeffrey SSee Remarks | Sell | 2,133 | $68.71 | $147K |
| Mar 18, 2026 | Lin Elizabeth YeuChief Medical Officer | Sell | 379 | $68.71 | $26K |
| Mar 17, 2026 | Azamian Bobak R.President/CEO and Board Chair | Sell | 10,972 | $69.42 | $762K |
| Mar 17, 2026 | Mottiwala AzizChief Commercial Officer | Sell | 4,286 | $69.42 | $298K |
| Mar 17, 2026 | Wahl BryanGeneral Counsel | Sell | 4,084 | $69.42 | $284K |
| Mar 17, 2026 | Whitfield Dianne C.Chief Human Resources Officer | Sell | 4,029 | $69.42 | $280K |
| Mar 17, 2026 | Neervannan SeshadriChief Operating Officer | Sell | 3,125 | $69.42 | $217K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.